Metastatic Hormone-sensitive Prostate Cancer Clinical Trial
Official title:
Open-label Study of Androgen Receptor Inhibition With dArolutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Men With Metastatic Hormone-Sensitive Prostate Cancer Using an External Control Arm
The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by progression-free survival. The researchers want to learn how long it takes for the cancer to get worse (also known as "progression-free survival") by either increasing symptoms, new metastases, PSA rise or death. All participants will be on treatment and take darolutamide with ADT until their cancer spreads, they have a medical problem, or they leave the study. The results will then be compared with patients' results from another study who received ADT alone (CHAARTED). This study will also assess safety by gathering adverse event information throughout the duration of the study. An adverse event is any medical problem, related or not to study treatment that a participant has during a study. The study drug, darolutamide, is already available for doctors to prescribe to patients with prostate cancer that has not yet spread to other parts of the body. It works by blocking a protein called a receptor from attaching to a hormone called androgen that is found in men. This protein can also be found in prostate cancer cells. ADT is a treatment that doctors are currently able to prescribe to patients with mHSPC. ADT is used to lower the amount of the androgen hormone.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05381311 -
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
|
||
| Active, not recruiting |
NCT00309985 -
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer
|
Phase 3 | |
| Completed |
NCT03532217 -
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
|
Phase 1 | |
| Completed |
NCT02799602 -
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT06134271 -
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04934722 -
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
|
Phase 3 | |
| Not yet recruiting |
NCT06334120 -
An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
|
||
| Recruiting |
NCT05901649 -
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
|
||
| Withdrawn |
NCT03343977 -
Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04191096 -
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
|
Phase 3 | |
| Active, not recruiting |
NCT03879122 -
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
|
Phase 2/Phase 3 |